Meeting
2021 Genitourinary Cancers Symposium
UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naïve prostate cancer (mHNPC).
Authors
Arun Azad
Peter MacCallum Cancer Center, Melbourne, VIC, Australia
Arun Azad , Nattakorn Dhiantravan , Louise Emmett , Anthony M. Joshua , Ian Vela , David A. Pattison , Roslyn J. Francis , Scott Williams , Shahneen Kaur Sandhu , Ian D. Davis , Nitika Neha , Mathias Bressel , Declan G. Murphy , Michael S Hofman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Advanced Prostate Cancer
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04343885
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS180)
DOI
10.1200/JCO.2021.39.6_suppl.TPS180
Abstract #
TPS180
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Teresa Alonso Gordoa
Poster
2021 Genitourinary Cancers Symposium
SPOP mutations in prostate cancer: Clinical and genomic features.
First Author: Mari Nakazawa
Poster
2018 ASCO Annual Meeting
A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle Frederick Burgess